Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06409247
Other study ID # 2023-052-PAU
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date June 30, 2026

Study information

Verified date May 2024
Source Palo Alto University
Contact Mikael Rubin, phD
Phone 650-433-3805
Email mrubin@paloaltou.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Social anxiety (SA) is a highly prevalent mental health concern, thought to disproportionately affect youth with recent international estimates of more than 30% of individuals reporting clinically elevated symptoms. Despite the prevalence of SA, as few as one in five individuals receive care, due to limited access to evidence-based treatments. Additionally there has been a notable increase in social anxiety since the start of the COVID-19 pandemic. This proposal will use iExposure to develop a personalized mechanism-focused approach to optimizing treatment response for individuals with social anxiety by testing standard iExposure against two augmentations that incorporate distinct attention mechanisms (attention guidance and attention control).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 390
Est. completion date June 30, 2026
Est. primary completion date June 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 or older - Fluent in English - Leibowitz Social Anxiety Scale > 47 and endorses both social anxiety items on the Web Screening Questionnaire for Common Mental Disorders Exclusion Criteria: - Currently receiving CBT for Social Anxiety Disorder - Significant visual impairment precluding engagement in the simulated teleconferencing interactions - Unstable dose of psychotropic medications within 6 weeks prior to baseline assessment - Current alcohol or substance use disorder - Current or past bipolar disorder or psychosis

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
iExposure
There will be 4 treatment sessions, covering the iExposure intervention. The intervention and assessment process is entirely self-guided. Each session will last approximately 60 minutes. Participants will complete 10 mock-interaction trials for each session.
iExposure plus attention guidance
The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
iExposure plus attention control
The attention control condition consists of two unique components in addition to the standard iExposure intervention (1) the intervention rationale will include information about the importance of developing attention control; (2) participants will be given a central region of the screen (non-audience member) to focus on. They will be told that they should look at and focus on the central region for the whole response.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Palo Alto University

Outcome

Type Measure Description Time frame Safety issue
Primary Liebowitz Social Anxiety Scale Self Report Version The Liebowitz Social Anxiety Scale Self Report Version is a 48-item self-report measure of fear and avoidance concerning social interactions and performance situations (e.g., telephoning in public, talking to people in authority). The range of scores is 0-144; higher scores are worse. 0 days
Primary Liebowitz Social Anxiety Scale Self Report Version The Liebowitz Social Anxiety Scale Self Report Version is a 48-item self-report measure of fear and avoidance concerning social interactions and performance situations (e.g., telephoning in public, talking to people in authority). The range of scores is 0-144; higher scores are worse. 15 days
Primary Liebowitz Social Anxiety Scale Self Report Version The Liebowitz Social Anxiety Scale Self Report Version is a 48-item self-report measure of fear and avoidance concerning social interactions and performance situations (e.g., telephoning in public, talking to people in authority). The range of scores is 0-144; higher scores are worse. 45 days
Primary Personal Report of Communication Apprehension (PRCA) The Personal Report of Communication Apprehension is a 24-item that assesses anxiety related to speaking in a variety of situation. The range of scores is 24-120; higher scores are worse. 0 days
Primary Personal Report of Communication Apprehension The Personal Report of Communication Apprehension is a 24-item that assesses anxiety related to speaking in a variety of situation. The range of scores is 24-120; higher scores are worse. 15 days
Primary Personal Report of Communication Apprehension The Personal Report of Communication Apprehension is a 24-item that assesses anxiety related to speaking in a variety of situation. The range of scores is 24-120; higher scores are worse. 45 days
Secondary Center for Epidemiologic Studies Depression Scale - Revised The Center for Epidemiologic Studies Depression Scale - Revised is a 20-item measure of depression. The range of scores is 0-60; higher scores are worse. 0 days
Secondary Center for Epidemiologic Studies Depression Scale - Revised The Center for Epidemiologic Studies Depression Scale - Revised is a 20-item measure of depression. The range of scores is 0-60; higher scores are worse. 15 days
Secondary Center for Epidemiologic Studies Depression Scale - Revised The Center for Epidemiologic Studies Depression Scale - Revised is a 20-item measure of depression. The range of scores is 0-60; higher scores are worse. 45 days
See also
  Status Clinical Trial Phase
Completed NCT05168020 - Evaluation of a Self-Monitoring Intervention to Reduce Safety Behavior in Social Anxiety N/A
Not yet recruiting NCT06020170 - Delving Into Participation Patterns in Social Anxiety Studies
Completed NCT03297619 - Self-help Books for Social Anxiety N/A
Completed NCT04509531 - Building Resilience in Cyberbullying Victims N/A
Recruiting NCT04859790 - Acceptability/Feasibility Testing of SCAR N/A
Completed NCT05576259 - oVRcome - Self Guided Virtual Reality for Social Anxiety Disorder N/A
Completed NCT05858294 - The Safety, Acceptability and Efficacy of Alena N/A
Completed NCT04450303 - Social Anxiety Telehealth Therapy Study N/A
Completed NCT03601377 - Attention Bias Modification Treatment in Social Anxiety N/A
Completed NCT03671577 - Building Closer Friendships in Social Anxiety Disorder N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Recruiting NCT05554718 - Evaluation of a Smartphone Application for Self-help for Social Anxiety N/A
Completed NCT02534948 - Feasibility Study of Mindfulness and Acceptance Based Group Therapy for Social Anxiety N/A
Completed NCT03249116 - Assessing Mechanisms of Anxiety Reduction in Animal-assisted Interventions N/A
Completed NCT05159037 - Using the Musical Track From GC-MRT as a Treatment Booster in Stressful Situations N/A
Completed NCT03711513 - Facing Fears by Focussing on Behaviour, Body, or Mind? N/A
Completed NCT04845100 - Animal Assisted Activities on the Stress and Social Anxiety N/A
Active, not recruiting NCT04276363 - Families, Children and Teachers Thriving Together N/A
Completed NCT05372744 - Affect-regulatory Characteristics of Deceptive Placebos N/A
Recruiting NCT05798078 - The Relationship Between Social Anxiety and Anxious Thinking Styles N/A